Infectious Disease Diagnostics Market Analysis

Infectious Disease Diagnostics Market Analysis

Infectious disease diagnostics market share from the reagents, kits & consumables segment was over USD 12 billion in 2022. This is attributed to the abundant availability of reagents, kits, and consumables for diagnosing several infectious diseases on the basis of exact targeted pathogens and conducted diagnostic tests. The growing adoption of RT-PCR in identifying RNA viruses including influenza, SARS-CoV-2, and hepatitis C will also add to the industry landscape. 
 

Infectious disease diagnostics market from respiratory disease applications will record 6% CAGR from 2023-2032. In recent years, there has been a significant rise in the number of pathogens that cause respiratory infections include bacteria, viruses, fungi, and parasites. Chest X-rays, such as CT scans, physical exams, and laboratory tests, including PCR testing of respiratory secretions and blood are increasingly employed as diagnostic tools to treat respiratory infections. The growing prominence of these tests for determining the origin of respiratory infections and offering the best course of actions will influence the industry scenario.
 

North America infectious disease diagnostics market is estimated to exceed USD 17 billion by 2032 due to the surging frequency of infectious diseases and the scaling deployment of cutting-edge diagnostic technologies. The rising healthcare costs and the rapidly expanding ageing population mainly in the U.S., Canada and Mexico will also boost the development of the regional market.